Nanospectra Biosciences Recognized as a ‘Houston Innovation Success’ at Congressional Healthcare Innovations Summit
HOUSTON, TX – February 21, 2019 – Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced that the company was the featured innovation success at the Congressional Healthcare Innovations Summit in Houston, Texas on February 21, 2019 at Rice University. The event, hosted by Texas Congressman Dan Crenshaw, brought together prominent members from industry, academia and government toshowcase major technological advancements and to celebrate innovation in Houston, Texas and beyond.
Congressman Dan Crenshaw delivered the keynote speech, which focused on the importance of nurturing innovation and ensuring our industry is not burdened by onerous regulations. Nanospectra Biosciences’ AuroLase® ultra-focal therapy for prostate cancer was highlighted as a Houston Innovation Success. David Jorden, Nanospectra’s CEO, was joined at the podium by Frank Billingsley, a Houston (NBC affiliate, KPRC) meteorologist and patient/participant in the AuroLase clinical trial at the University of Texas Health Science Center. Frank shared his moving story on what it means to him to have a therapy that maximizes patient benefits while minimizing side effects and preserving his quality of life.
“Nanospectra is honored to be highlighted as an example of healthcare innovation in the Houston area, and more specifically, for the continued development of its underlying technology originally developed locally at Rice University,” said David Jorden. “Congressman Crenshaw’s strong commitment to innovation provides meaningful support to our efforts and those of others working to bring valuable change to patient-centric healthcare therapies and improved patient outcomes.”
About Nanospectra Biosciences
Nanospectra Biosciences is a privately-held medical device company, pioneering the patient-centric use of nanomedicine for selective thermal ablation. AuroLase®, the company’s lead product, is the first ultra-focal therapy for prostate cancer. Nanospectra’s ultra-focal approach maximizes treatment efficacy while minimizing side effects associated with current treatments, including surgery, radiation, and traditional focal therapies. Implementing a multi-prong growth strategy, Nanospectra is focusing on clinical advancements, exclusive partnering agreements and ongoing research and development. Nanospectra’s technology development has been funded to date by a series of grants, private equity investments and corporate partnerships. For more information visit http://www.nanospectra.